Shanghai Zhangjiang, Boehringer To Partner In $81.4 China Facility
This article was originally published in PharmAsia News
Executive Summary
Shanghai Zhangjiang Biotech is joining with Boehringer Ingelheim and Pharmaceutical Base Development to build an $81.4 million China production and research-and-development facility for a broad range of health products.